Molecular modeling and virtual screening of DNA methyltransferase inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 12, 2013, Pages 2138-2147

  Medina Franco, José L ^a   Yoo, Jakyung ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Chemoinformatics; Docking; Drug discovery; Epigenetics; Homology modeling; Molecular dynamics; Protein ligand interaction fingerprints; Virtual screening

Indexed keywords

3 METHYLCHOLANTHRENE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CURCUMIN; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; HYDRALAZINE; MAHANINE; N PHTHALOYLTRYPTOPHAN; NANAOMYCIN A; NSC 106084; NSC 137546; NSC 138419; NSC 14778; NSC 154957; NSC 154962; NSC 158324; NSC 19555; NSC 27292; NSC 303530; NSC 319745; NSC 345763; NSC 348926; NSC 408488; NSC 4092; NSC 54162; NSC 56071; NSC 57278; NSC 57893; NSC 622444; NSC 97317; PARTHENOLIDE; PROCAINAMIDE; PROCAINE; RG 108 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZEBULARINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CHEMICAL ANALYSIS; CRYSTAL STRUCTURE; DNA METHYLATION; DRUG SCREENING; ENZYME INHIBITION; EPIGENETICS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MODIFICATION METHYLASES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; LIGANDS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876740124     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319120002     Document Type: Article

References (86)

1. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20: 3139-55.
2. Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. ChemBioChem 2011; 12: 206-22.
3. Foulks JM, Parnell KM, Nix RN, et al. Epigenetic drug discovery. J Biomol Screening 2012; 17: 2-17.
4. Martinet N, Michel BY, Bertrand P, Benhida R. Small molecules DNA methyltransferases inhibitors. MedChemComm 2012; 3: 263-73.
5. Chen TP, Hevi S, Gay F, et al. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet 2007; 39: 391-6.
6. Cheng XD, Blumenthal RM. Mammalian DNA methyltransferases: A structural perspective. Structure 2008; 16: 341-50.
7. Schaefer M, Lyko F. Solving the Dnmt2 enigma. Chromosoma 2010; 119: 35-40.
8. Goll MG, Kirpekar F, Maggert KA, et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006; 311: 395-8.
9. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
10. Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets 2011; 12: 1925-56.
11. Ren J, Singh BN, Huang Q, et al. DNA hypermethylation as a chemotherapy target. Cell Signal 2011; 23: 1082-93.
12. Khan SI, Aumsuwan P, Khan IA, Walker LA, Dasmahapatra AK. Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chem Res Toxicol 2012; 25: 61-73.
13. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005; 97: 1498-506.
14. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-68.
15. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28: 1069-78.
16. Song J, Rechkoblit O, Bestor TH, Patel DJ. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 2011; 331: 1036-40.
17. Sippl W, Jung M, Eds. Epigenetic Targets in Drug Discovery. Weinheim: Wiley-VCH 2009.
18. Lan J, Hua S, He XN, Zhang Y. DNA methyltransferases and methyl-binding proteins of mammals. Acta Biochim Biophys Sin 2010; 42: 243-52.
19. Vilkaitis G, Merkiene E, Serva S, Weinhold E, Klimasauskas S. The mechanism of DNA cytosine-5 methylation. Kinetic and mutational dissection of HhaI methyltransferase. J Biol Chem 2001; 276: 20924-34.
20. Schermelleh L, Spada F, Easwaran HP, et al. Trapped in action: Direct visualization of DNA methyltransferase activity in living cells. Nat Methods 2005; 2: 751-6.
21. Issa J-PJ, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938-46.
22. Yang XJ, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010; 31: 536-46.
23. Song SH, Han SW, Bang YJ. Epigenetic-based therapies in cancer progress to date. Drugs 2011; 71: 2391-403.
24. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123: 8-13.
25. Issa JPJ, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discovery 2005; 4: 275-6.
26. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-85.
27. Issa J-P. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: Dose, duration, and patient selection. Nat Clin Pract Oncol 2005; 2 Suppl 1: S24-9.
28. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114: 2764-73.
29. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008; 28: 752-71.
30. Suzuki T, Tanaka R, Hamada S, Nakagawa H, Miyata N. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg Med Chem Lett 2010; 20: 1124-7.
31. Yu N, Wang M. Anticancer drug discovery targeting DNA hypermethylation. Curr Med Chem 2008; 15: 1350-75.
32. Hauser AT, Jung M. Targeting epigenetic mechanisms: Potential of natural products in cancer chemoprevention. Planta Med 2008; 74: 1593-601.
33. Castellano S, Kuck D, Viviano M, et al. Synthesis and biochemical evaluation of e2-isoxazoline derivatives as DNA methyltransferase 1 inhibitors. J Med Chem 2011; 54: 7663-77.
34. Dueñas-Gonzáez A, García-López P, Herrera LA, Medina-Franco JL, González-Fierro A, Candelaria M. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 2008; 7: 82.
35. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003; 9: 1596-603.
36. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003; 63: 4984-9.
37. Lee BH, Yegnasubramanian S, Lin XH, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005; 280: 40749-56.
38. Gilbert ER, Liu D. Flavonoids influence epigenetic-modifying enzyme activity: Structure-function relationships and the therapeutic potential for cancer. Curr Med Chem 2010; 17: 1756-68.
39. Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem 2010; 17: 2141-51.
40. Fang MZ, Wang YM, Ai N, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-70.
41. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 2005; 68: 1018-30.
42. Liu ZF, Xie ZL, Jones W, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett 2009; 19: 706-9.
43. Medina-Franco J, López-Vallejo F, Kuck D, Lyko F. Natural products as DNA methyltransferase inhibitors: A computer-aided discovery approach. Mol Diversity 2011; 15: 293-304.
44. Kuck D, Caulfield T, Lyko F, Medina-Franco JL. Nanaomycin a selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 2010; 9: 3015-23.
45. Medina-Franco JL, Caulfield T. Advances in the computational development of DNA methyltransferase inhibitors. Drug Discovery Today 2011; 16: 418-25.
46. Tang MQ, Xu W, Wang QZ, Xiao WD, Xu RA. Potential of DNMT and its epigenetic regulation for lung cancer therapy. Current Genomics 2009; 10: 336-52.
47. Siedlecki P, Boy RG, Musch T, et al. Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 2006; 49: 678-83.
48. Kuck D, Singh N, Lyko F, Medina-Franco JL. Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem 2010; 18: 822-9.
49. Rundfeldt C, Ed. Drug development-a case study based insight into modern strategies [book on the internet]. InTech: 2011 [cited 2012 Sep 18]. Available from: http://www.intechopen.com/articles/show/title/discovery-and optimization-of-inhibitors-of-dna-methyltransferase-as-noveldrugs-for-cancer-therapy
50. Siedlecki P, Boy RG, Comagic S, et al. Establishment and functional validation of a structural homology model for human DNA methyltransferase 1. Biochem Biophys Res Commun 2003; 306: 558-63.
51. Kumar S, Cheng XD, Klimasauskas S, et al. The DNA (cytosine-5) methyltransferases. Nucleic Acids Res 1994; 22: 1-10.
52. Singh N, Dueñas-González A, Lyko F, Medina-Franco JL. Molecular modeling and dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem 2009; 4: 792-9.
53. Liu ZF, Liu SJ, Xie ZL, et al. Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther 2009; 329: 505-14.
54. Yoo J, Medina-Franco JL. Homology modeling, docking, and structure-based pharmacophore of inhibitors of DNA methyltransferase. J Comput-Aided Mol Des 2011; 25: 555-67.
55. Yoo J, Medina-Franco JL. Trimethylaurintricarboxylic acid inhibits human DNA methyltransferase 1: Insights from enzymatic and molecular modeling studies. J Mol Model 2012; 18: 1583-9.
56. Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007; 449: 248-51.
57. Klimasauskas S, Kumar S, Roberts RJ, Cheng XD. Hhal methyltransferase flips its target base out of the DNA helix. Cell 1994; 76: 357-69.
58. Hernández-Campos A, Velázquez-Martínez I, Castillo R, et al. Docking of protein kinase B inhibitors: Implications in the structure-based optimization of a novel scaffold. Chem Biol Drug Des 2010; 76: 269-76.
59. Yoo J, Kim JH, Robertson KD, Medina-Franco JL. Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: Discovery of a novel DNMT1 inhibitor. Adv Protein Chem Struct Biol 2012; 87: 219-47.
60. Salam NK, Nuti R, Sherman W. Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model 2009; 49: 2356-68.
61. López-Vallejo F, Caulfield T, Martínez-Mayorga K, et al. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. Comb Chem High Throughput Screening 2011; 14: 475-87.
62. Evans DA, Bronowska AK. Implications of fast-time scale dynamics of human DNA/RNA cytosine methyltransferases (DNMTs) for protein function. Theor Chem Acc 2010; 125: 407-18.
63. Engel T. Basic overview of chemoinformatics. J Chem Inf Model 2006; 46: 2267-77.
64. Willett P. Chemoinformatics: A history. WIREs Comput Mol Sci 2011; 1: 46-56.
65. Reymond J-L, van Deursen R, Blum LC, Ruddigkeit L. Chemical space as a source for new drugs. Med Chem Comm 2010; 1: 30-8.
66. Medina-Franco JL, Martínez-Mayorga K, Giulianotti MA, Houghten RA, Pinilla C. Visualization of the chemical space in drug discovery. Curr Comput-Aided Drug Des 2008; 4: 322-33.
67. Martínez-Mayorga K, Peppard TL, Yongye AB, Santos R, Giulianotti M, Medina-Franco JL. Characterization of a comprehensive flavor database. J Chemom 2011; 25: 550-60.
68. López-Vallejo F, Giulianotti MA, Houghten RA, Medina-Franco JL. Expanding the medicinally relevant chemical space with compound libraries. Drug Discovery Today 2012; 17: 718-26.
69. Rabal O, Oyarzabal J. Using novel descriptor accounting for ligand-receptor interactions to define and visually explore the biologically relevant chemical space. J Chem Inf Model 2012; 52: 1086-102.
70. Scior T, Bernard P, Medina-Franco JL, Maggiora GM. Large compound databases for structure-activity relationships studies in drug discovery. Mini-Rev Med Chem 2007; 7: 851-60.
71. DNMT-Focused Library [homepage on the internet]. ChemDiv Inc.; 2011 [cited 2012 Sep 18]. Available from: http://eu.chemdiv.com/
72. Fourches D, Muratov E, Tropsha A. Trust, but verify: On the importance of chemical structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model 2010; 50: 1189-204.
73. Irwin JJ, Shoichet BK. ZINC-A free database of commercially available compounds for virtual screening. J Chem Inf Model 2005; 45: 177-82.
74. Wishart DS, Knox C, Guo AC, et al. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901-D6.
75. Developmental Therapeutics Program [homepage on the internet]. National Cancer Institute (NIH) [cited 2012 Sep 18]. Available from: http://dtp.cancer.gov
76. Medina-Franco JL, Martínez-Mayorga K, Bender A, et al. Characterization of activity landscapes using 2D and 3D similarity methods: Consensus activity cliffs. J Chem Inf Model 2009; 49: 477-91.
77. Yoo J, Medina-Franco JL. Chemoinformatic approaches for inhibitors of DNA methyltransferases: Comprehensive characterization of screening libraries. Comp Mol Biosci 2011; 1: 7-16. Available from: http://www.scirp.org/journal/ PaperInformation.aspx?paperID=16496&publishStatus=2#abstract
78. Brewerton SC. The use of protein-ligand interaction fingerprints in docking. Curr Opin Drug Discov Dev 2008; 11: 356-64.
79. Molecular Operating Environment (MOE), version 2011.10, Chemical Computing Group Inc., Montreal, Quebec, Canada.
80. Spotfire, version 9.1.1, TIBCO Software, Inc., Somerville, MA.
81. Scior T, Bender A, Tresadern G, et al. Recognizing pitfalls in virtual screening: A critical review. J Chem Inf Model 2012; 52: 867-81.
82. López-Vallejo F, Nefzi A, Bender A, et al. Increased diversity of libraries from libraries: Chemoinformatic analysis of bisdiazacyclic libraries. Chem Biol Drug Des 2011; 77: 328-42.
83. Houghten RA, Pinilla C, Giulianotti MA, et al. Strategies for the use of mixture-based synthetic combinatorial libraries: Scaffold ranking, direct testing, in vivo, and enhanced deconvolution by computational methods. J Comb Chem 2008; 10: 3-19.
84. Willett P. Similarity-based virtual screening using 2D fingerprints. Drug Discovery Today 2006; 11: 1046-53.
85. Yoo J, Medina-Franco JL. Towards the chemoinformatic-based identification of DNA methyltransferase inhibitors: 2D-and 3Dsimilarity profile of screening libraries. Curr Comput-Aided Drug Des 2012; 8: 317-29.
86. Datta J, Ghoshal K, Denny WA, et al. A new class of quinolinebased DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res 2009; 69: 4277-85.